NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyMedications Development for the Treatment of Cannabis-Related Disorders (R01)
National Institutes of Health
About This Grant
Purpose: This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA), National Institutes of Health, solicits new or competing renewal Research Project Grant (R01) applications from institutions/ organizations that propose to conduct preclinical and clinical research directed towards the identification, evaluation and development of safe and effective medications for the treatment of Cannabis Related Disorders (CRDs) and their medical and psychiatric consequences. They include the Cannabis Use Disorders (CUDs) such cannabis abuse and dependence, the Cannabis Induced Disorders (CIDs) such as intoxication, psychosis, and anxiety, as well as the comorbidity of these disorders with other medical and psychiatric disorders (e.g., depression). Cannabis use includes marijuana, hashish, and other tetrahydrocannabinol (THC) containing substances. NIDA is encouraging research in this area because there is a high prevalence of marijuana use in the general population accompanied with an increasing misperception that its use poses low health risk, there is limited research in this area, and there are no effective pharmacological treatments available for these disorders. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-07-366, that solicits applications under the R21 mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organizations; Other(s): Eligible agencies of the Federal government; Faith-based or community based organizations. Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct. Renewals and Resubmissions. Applications can be renewed by competing for additional project periods. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement).
Grant Summary
Medications Development for the Treatment of Cannabis-Related Disorders (R01) is a National Institutes of Health grant providing funding that varies by award for municipality. Applications are accepted on a rolling basis. Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
Requirements
- must include an Introduction addressing the previous peer review critique (Summary Statement)
- application must include an Introduction addressing the previous peer review critique (Summary Statement)
- peer review
How to Apply
Up to $0K
Rolling / Open
- 1Confirm your organization is eligible for Medications Development for the Treatment of Cannabis-Related Disorders (R01) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Medications Development for the Treatment of Cannabis-Related Disorders (R01): Frequently Asked Questions
Who is eligible for the Medications Development for the Treatment of Cannabis-Related Disorders (R01)?
Medications Development for the Treatment of Cannabis-Related Disorders (R01) is offered by National Institutes of Health and is generally open to municipality. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Medications Development for the Treatment of Cannabis-Related Disorders (R01) provide?
Medications Development for the Treatment of Cannabis-Related Disorders (R01) provides an amount that varies by award per award from National Institutes of Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Medications Development for the Treatment of Cannabis-Related Disorders (R01) deadline?
Medications Development for the Treatment of Cannabis-Related Disorders (R01) accepts applications on a rolling or ongoing basis, so there is no single fixed deadline. Confirm current timing with the funder, National Institutes of Health, before you apply, and submit as early as possible because rolling programs can close once funds are committed.
How do you apply for the Medications Development for the Treatment of Cannabis-Related Disorders (R01)?
To apply for Medications Development for the Treatment of Cannabis-Related Disorders (R01), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.